| Thomas Carlson, MD | |
|
820 N Chelan Ave, Wenatchee, WA 98801-2028 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Thomas Carlson |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 25 Years |
| Location | 820 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073540704 | NPI | - | NPPES |
| P01256585 | Other | WA | RR MEDICARE |
| 1073540704 | Medicaid | WA | |
| 315460 | Other | WA | L&I POST 7/21/13 |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | MD00043266 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Washington Hospital | Wenatchee, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Washington Health Services Association | 4880504596 | 645 |
News Archive
Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
Like a child awaiting the arrival of Christmas, embryonic stem cells exist in a state of permanent anticipation. They must balance the ability to quickly become more specialized cell types with the cellular chaos that could occur should they act too early (stop shaking those presents, kids!).
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
› Verified 4 days ago
| Entity Name | Central Washington Health Services Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
Like a child awaiting the arrival of Christmas, embryonic stem cells exist in a state of permanent anticipation. They must balance the ability to quickly become more specialized cell types with the cellular chaos that could occur should they act too early (stop shaking those presents, kids!).
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
› Verified 4 days ago
| Entity Name | Wenatchee Valley Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
Like a child awaiting the arrival of Christmas, embryonic stem cells exist in a state of permanent anticipation. They must balance the ability to quickly become more specialized cell types with the cellular chaos that could occur should they act too early (stop shaking those presents, kids!).
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Carlson, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: () - | Thomas Carlson, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 |
News Archive
Avicena Group, Inc. has announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent #7,285,573 for the use of the Company's proprietary drug candidates for the treatment of amyotrophic lateral sclerosis ("ALS" or "Lou Gehrig's Disease").
Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.
Like a child awaiting the arrival of Christmas, embryonic stem cells exist in a state of permanent anticipation. They must balance the ability to quickly become more specialized cell types with the cellular chaos that could occur should they act too early (stop shaking those presents, kids!).
In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside.
› Verified 4 days ago
Dr. Gary K. Lammert, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Central Washington Hospital, Wenatchee, WA 98801 Phone: 509-664-3472 Fax: 509-665-6211 | |
John T Register, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Olaseni Arogundade, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Fred P Bockenstedt, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Daniel William Brown, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Ian Cunningham, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |